Differences in Clinical Characteristics and Outcomes Between Men and Women With Idiopathic Pulmonary Fibrosis

A Multicenter Retrospective Cohort Study
Published:February 18, 2020DOI:https://doi.org/10.1016/j.chest.2020.02.009

      Background

      Idiopathic pulmonary fibrosis (IPF) is a disease with a male predominance. Prior data suggest that male sex is associated with disease progression and survival. The basis for this sex difference is unknown.

      Research Question

      Are there differences in clinical disease characteristics and outcomes between men and women with IPF?

      Study Design and Methods

      Two tertiary care center IPF cohorts were pooled to analyze sex differences in outcomes of time to lung transplantation or death. Predictors of outcome that were analyzed included age, FVC % predicted, diffusion capacity for carbon monoxide (D lco) % predicted, BMI, smoking history, and respiratory variables of cough, phlegm, and need for supplemental oxygen. The associations of these factors with mortality were estimated by sex and then compared using tests for interaction.

      Results

      There were a total of 1,263 patients in the pooled cohort with follow-up data; approximately 71% of the patients were men. Male sex was independently associated with higher risk for death or lung transplantation after adjusting for age, FVC % predicted, and D lco % predicted (hazard ratio for men, 1.4; 95% CI, 1.2-1.7; P < .001). Older age, lower D lco % predicted, and presence of cough or phlegm were negatively associated with transplant-free survival in men but not in women, but only the association for cough differed statistically by sex (interaction P = .007).

      Interpretation

      Male sex is associated with worse transplant-free survival in IPF. Cough may be a sex-specific predictor of survival in this population.

      Key Words

      Abbreviations:

      Dlco ( diffusion capacity of the lung for carbon monoxide), HR ( hazard ratio), IPF ( idiopathic pulmonary fibrosis), UCSD-SOBQ ( University of California San Diego Shortness of Breath Questionnaire), UCSF ( University of California San Francisco)
      To read this article in full you will need to make a payment
      Subscribe to CHEST
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • King Jr., T.E.
        • Pardo A.
        • Selman M.
        Idiopathic pulmonary fibrosis.
        Lancet. 2011; 378: 1949-1961
        • Jo H.E.
        • Glaspole I.
        • Grainge C.
        • et al.
        Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry.
        Eur Respir J. 2017; 49
        • Baumgartner K.B.
        • Samet J.M.
        • Stidley C.A.
        • Colby T.V.
        • Waldron J.A.
        Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis.
        Am J Respir Crit Care Med. 1997; 155: 242-248
        • Ekstrom M.
        • Gustafson T.
        • Boman K.
        • et al.
        Effects of smoking, gender and occupational exposure on the risk of severe pulmonary fibrosis: a population-based case-control study.
        BMJ Open. 2014; 4e004018
        • Han M.K.
        • Murray S.
        • Fell C.D.
        • et al.
        Sex differences in physiological progression of idiopathic pulmonary fibrosis.
        Eur Respir J. 2008; 31: 1183-1188
        • Moua T.
        • Zamora Martinez A.C.
        • Baqir M.
        • Vassallo R.
        • Limper A.H.
        • Ryu J.H.
        Predictors of diagnosis and survival in idiopathic pulmonary fibrosis and connective tissue disease-related usual interstitial pneumonia.
        Respir Res. 2014; 15: 154
        • Lee J.W.
        • Shehu E.
        • Gjonbrataj J.
        • et al.
        Clinical findings and outcomes in patients with possible usual interstitial pneumonia.
        Respir Med. 2015; 109: 510-516
        • Raghu G.
        • Remy-Jardin M.
        • Myers J.L.
        • et al.
        Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline.
        Am J Respir Crit Care Med. 2018; 198: e44-e68
        • Swigris J.J.
        • Han M.
        • Vij R.
        • et al.
        The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis.
        Respir Med. 2012; 106: 1447-1455
        • Zaman T.
        • Collard H.R.
        • Lee J.S.
        Sex-specific predictors of death in idiopathic pulmonary fibrosis.
        Am J Respir Crit Care Med. 2018; 197: A1607
        • Camelo A.
        • Dunmore R.
        • Sleeman M.A.
        • Clarke D.L.
        The epithelium in idiopathic pulmonary fibrosis: breaking the barrier.
        Front Pharmacol. 2014; 4: 173
        • Raghu G.
        • Weycker D.
        • Edelsberg J.
        • Bradford W.Z.
        • Oster G.
        Incidence and prevalence of idiopathic pulmonary fibrosis.
        Am J Respir Crit Care Med. 2006; 174: 810-816
        • Redente E.F.
        • Jacobsen K.M.
        • Solomon J.J.
        • et al.
        Age and sex dimorphisms contribute to the severity of bleomycin-induced lung injury and fibrosis.
        Am J Physiol Lung Cell Mol Physiol. 2011; 301: L510-L518
        • Ryerson C.J.
        • Abbritti M.
        • Ley B.
        • Elicker B.M.
        • Jones K.D.
        • Collard H.R.
        Cough predicts prognosis in idiopathic pulmonary fibrosis.
        Respirology. 2011; 16: 969-975
        • Nathan S.D.
        • Albera C.
        • Bradford W.Z.
        • et al.
        Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.
        Lancet Respir Med. 2017; 5: 33-41
        • Lancaster L.
        • Crestani B.
        • Hernandez P.
        • et al.
        Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials.
        BMJ Open Respir Res. 2019; 6e000397
        • Costabel U.
        • Inoue Y.
        • Richeldi L.
        • et al.
        Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS.
        Am J Respir Crit Care Med. 2016; 193: 178-185
        • Vancheri C.
        • Sebastiani A.
        • Tomassetti S.
        • et al.
        Pirfenidone in real life: a retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis.
        Respir Med. 2019; 156: 78-84